Clinical Guides
Organophosphorus Poisoning
A clinically focused Indian guide to recognising and stabilising acute organophosphorus pesticide poisoning, with titrated antidotes, safe decontamination and planned respiratory surveillance.
MedNext Academy | 15 min read
Organophosphorus Poisoning
A clinically focused Indian guide to recognising and stabilising acute organophosphorus pesticide poisoning, with titrated antidotes, safe decontamination and planned respiratory surveillance.
Summary
Organophosphorus poisoning is a time-critical toxidrome caused by inhibition of acetylcholinesterase, accumulation of acetylcholine and overstimulation of muscarinic, nicotinic and central receptors. In India, exposure commonly involves agricultural insecticides through deliberate ingestion, unsafe storage, occupational skin or inhalational contact, or accidental childhood access. The label or container matters because pesticide formulations may contain solvents and because carbamates, pyrethroids, aluminium phosphide and other products can resemble or accompany organophosphorus exposure. Never delay resuscitation while trying to identify the exact compound.
The lethal problems are secretions and bronchospasm, aspiration, central respiratory depression, neuromuscular weakness, seizures, dysrhythmia and shock. A wet patient with pinpoint pupils, fasciculation, bradycardia and diarrhoea is recognisable, but neither miosis nor bradycardia is required. Tachycardia may reflect hypoxia, solvent effects or prior atropine. Immediate priorities are rescuer protection, removal from ongoing exposure, airway suction and oxygenation, ventilation when required, circulation support and rapid atropine titrated to a clear chest and adequate perfusion. Atropine treats muscarinic physiology; it does not reverse nicotinic weakness.
Oxime treatment is more uncertain. Pralidoxime can reactivate acetylcholinesterase before the inhibited enzyme ages, yet trials have produced conflicting results across compounds, delays and regimens. It should follow the current poison-centre and institutional toxicology protocol rather than replace airway care or atropine. Observe beyond initial apparent recovery for recurrent cholinergic toxicity, intermediate syndrome and delayed neuropathy. Every intentional exposure requires compassionate suicide-risk assessment after medical stabilisation, restriction of access to the pesticide and a safe follow-up plan. This quarantined educational draft does not replace immediate advice from an Indian poison information centre or a treating toxicologist.
How Common Is It?
Acute pesticide intoxication remains an important emergency in agricultural regions, but a trustworthy current national incidence for organophosphorus poisoning cannot be derived from one hospital series or a poison-centre call count. Studies variously include suspected cases, mixed pesticides, only admitted patients or only deaths; some use an odour or bedside syndrome without analytical identification. Referral hospitals over-represent severe ingestion, whereas occupational and low-dose exposures may never reach surveillance. Cause-of-death coding may record poisoning without naming the chemical. These differences make simple rankings or national percentages misleading.
WHO describes pesticide self-poisoning as a major preventable contributor to suicide in parts of the world where highly hazardous products are readily accessible. The clinical burden is concentrated in settings where a large amount can be ingested before rescue and where transport, ventilation or antidote supply is delayed. Indian risk is therefore not uniform: crop pattern, local pesticide sales, storage practice, rural transport, poison-centre access and intensive-care capacity all alter outcome.
A service should measure exposures by named formulation, route, intent, time to first care, atropine requirement, ventilation, complications and outcome. Call volume is not population incidence, and falling admissions may reflect safer regulation or poorer access. The actionable conclusion is that any district receiving pesticide cases needs PPE, suction, oxygen, rapidly available atropine, an escalation route and contact details for a poison information centre before the next patient arrives.
Risk Factors
The largest acute dose usually follows intentional ingestion of a concentrated agricultural formulation. Risk increases when pesticides are stored unlocked in homes, decanted into beverage bottles, sold in large containers or kept near a person in crisis. Previous self-harm, depression, alcohol misuse, interpersonal violence, debt, crop loss, impulsivity and poor access to mental-health care are relevant, but clinicians must not stereotype rural patients or assume intent. A non-judgemental private history is more reliable than an accusatory interview. Restricting immediate access after discharge is a clinical safety intervention.
Occupational exposure occurs during mixing, spraying, equipment cleaning, spill response or re-entry into treated areas, especially without gloves, protective clothing, eye protection or washing facilities. Heat can discourage PPE and increase dermal absorption through sweating. Children may ingest a product, touch contaminated clothing or be exposed during unsafe home spraying. Dermal poisoning may evolve more slowly than ingestion, and a symptom-free interval does not establish safety when the formulation or dose is uncertain.
Severity depends on compound, concentration, amount, route, delay to decontamination, ageing kinetics, fat solubility and co-formulants. Aspiration, pre-hospital emesis, hypoxia and delayed ventilation worsen prognosis. Co-ingestion of alcohol, sedatives or another pesticide can obscure the cholinergic pattern. Pregnancy, childhood, frailty, cardiac disease and limited respiratory reserve complicate management. Staff and relatives are at risk from contaminated clothes, skin, gastric contents and vapour; inadequate PPE can create secondary casualties. A remote clinic without suction, oxygen, monitoring or transport has a systems risk even before patient-level factors are considered.
Diagnosis
Diagnosis is clinical and treatment-sensitive physiology should be corrected before laboratory confirmation. The useful question is whether acetylcholine excess explains the respiratory, secretory, neuromuscular and neurological findings, while parallel assessment searches for aspiration, trauma, hypoglycaemia and a different or mixed poison.
History
Ask what product was involved, the trade and generic names, formulation strength, amount missing, route, time, whether vomiting occurred and what first aid was attempted. Request a photograph or sealed container without allowing contaminated packaging into a clean clinical area. Establish spraying, mixing or clothing exposure and whether other people are symptomatic. Ask about alcohol, medicines, other pesticides, pregnancy, epilepsy, lung disease and prior self-harm. Do not rely on garlic-like or solvent odour. Obtain collateral information without delaying care, preserve privacy and document uncertainty rather than converting a guess into a confirmed ingestion.
Examination
Use an ABCDE approach with continuous oxygen saturation, respiratory rate, blood pressure, heart rate, temperature, mental state and ECG monitoring in significant poisoning. Listen for diffuse bronchorrhoea and wheeze; inspect secretions, work of breathing and vomiting; assess gag and airway protection. Record pupils but do not use pupil size as the atropine target. Muscarinic findings include salivation, lacrimation, sweating, bronchospasm, vomiting, abdominal cramp, diarrhoea, urination and bradycardia. Nicotinic findings include fasciculation, weakness, tachycardia and hypertension. Central effects include anxiety, confusion, ataxia, seizures, coma and respiratory drive failure. Repeatedly test proximal power, especially neck flexion, and measure ventilation where feasible because intermediate syndrome may emerge after the initial crisis.
Investigations
Obtain bedside glucose, ECG, blood gas or lactate, electrolytes, renal and liver function, full blood count and chest imaging when aspiration or pulmonary oedema is suspected. Serial vital capacity, tidal volume or blood gases can support respiratory decisions but should not postpone intubation in an exhausted patient. Plasma butyrylcholinesterase is often accessible and can support exposure; red-cell acetylcholinesterase better reflects synaptic enzyme but is less available. Neither result reliably grades bedside severity, identifies the compound or should delay atropine. Save an appropriately labelled sample if analytical toxicology is available after poison-centre discussion. Consider pregnancy testing when relevant, creatine kinase after prolonged seizures or immobility, and targeted tests for co-ingestants. A normal early chest radiograph does not exclude evolving aspiration.
Differential Diagnosis
Carbamate insecticides also inhibit cholinesterase and can produce an almost identical cholinergic crisis; toxicity is often shorter because enzyme binding is reversible, but bedside differentiation is unreliable and atropine remains physiology-directed. Nicotine or neonicotinoid exposure, nerve agents and certain medicinal cholinesterase inhibitors can share features. Pyrethroid poisoning more often causes paraesthesia, tremor, salivation and seizures without the same sustained cholinesterase inhibition. Aluminium phosphide causes profound shock, metabolic acidosis and myocardial toxicity but not a classic wet cholinergic syndrome.
Opioid poisoning can cause miosis and respiratory depression, yet usually produces dry skin and reduced bowel activity rather than bronchorrhoea, sweating, diarrhoea and fasciculation. Pontine haemorrhage may cause coma and tiny pupils but has focal neurological or imaging findings. Brainstem infection, status epilepticus, hypoglycaemia, heat illness and severe sepsis can present with altered consciousness. Myasthenic crisis, botulism, Guillain-Barre syndrome and snake envenoming cause weakness but lack the complete muscarinic pattern.
Acute asthma, cardiogenic pulmonary oedema and aspiration can explain wheeze or wet lungs. Atropine itself can later cause delirium, hyperthermia, dry flushed skin, urinary retention, absent bowel sounds and tachycardia; these findings must be distinguished from persistent poisoning. Intermediate syndrome is not recurrent muscarinic excess: it is delayed proximal, neck and respiratory muscle weakness after the acute phase and may occur with relatively dry lungs. Organophosphate-induced delayed neuropathy appears one to several weeks later with distal sensory-motor symptoms and requires neurological assessment rather than more atropine.
Management
Protect the team first. Move away from the source, use gloves, fluid-resistant gown or apron and eye or face protection, remove contaminated clothing and bag it safely, then wash exposed skin and hair thoroughly with soap and water. Irrigate exposed eyes with clean water or saline. Keep decontamination separate from the resuscitation zone and avoid unprotected contact with vomit. Rescuers should not induce vomiting or give drinks. If there is a tension between decontamination and a failing airway, life-saving resuscitation with appropriate PPE takes priority.
Suction secretions, give oxygen and assist ventilation early. Intubate for inability to protect the airway, refractory hypoxaemia, severe bronchorrhoea, seizures, declining consciousness, apnoea or progressive neuromuscular weakness. Pre-oxygenate and anticipate aspiration. Succinylcholine can be markedly prolonged when cholinesterase is inhibited, so the airway clinician should select a non-depolarising strategy under the local rapid-sequence protocol. Give isotonic crystalloid for hypotension while assessing pulmonary status; add vasopressor support for persistent shock. Treat seizures with a benzodiazepine and correct glucose or electrolyte disturbances.
Atropinise rapidly using repeated intravenous boluses, escalating by clinical response rather than waiting on a fixed cumulative ceiling. Desired early endpoints are clearing of bronchial secretions and bronchospasm, improving oxygenation, heart rate and systolic pressure sufficient for perfusion. Dry mouth, dilated pupils or tachycardia alone are poor endpoints. Once stabilised, start a titrated infusion based on the total effective loading dose and adjust frequently for recurrent wet chest or toxicity. Consider pralidoxime early in moderate or severe confirmed or strongly suspected organophosphorus poisoning after toxicology advice; never delay atropine to obtain it.
Routine gastric lavage is unsafe before resuscitation and airway protection, and evidence of benefit is weak. Activated charcoal or lavage should be exceptional poison-centre decisions based on a potentially lethal recent ingestion, protected airway and local expertise. Monitor in a high-dependency or intensive-care setting when antidote infusion, oxygen, weakness or altered consciousness is present. After survival, assess intent, capacity, ongoing suicide risk, safeguarding, pesticide access and family support before a collaborative discharge.
Prescribing Information
For an adult with clinically important muscarinic toxicity, the Eddleston clinical regimen starts atropine 1 to 3 mg intravenously according to severity. Reassess chest sounds, secretions, oxygenation, pulse and blood pressure after three to five minutes; if targets are not improving, double the previous dose and repeat at the same interval until atropinisation. A referenced paediatric starting dose is 0.02 mg/kg intravenously, but children require senior paediatric and poison-centre oversight. Large cumulative doses may be necessary. Do not underdose because a conventional vial count looks unusual, and do not chase normal pupils.
After adequate loading, start an atropine infusion at approximately 10 to 20 percent of the total loading dose per hour. Review at least every 15 minutes initially and after any change. Recurrent bronchorrhoea, bronchospasm, bradycardia or hypotension requires bolus re-atropinisation and infusion escalation. Delirium, pyrexia, absent bowel sounds, urinary retention and a dry hot patient suggest excess; pause or reduce under continuous observation, while remembering that hypoxia, sepsis and withdrawal can also cause agitation. Record every bolus and the running total because calculation errors can be fatal.
A commonly cited adult pralidoxime-chloride regimen is 2 g intravenously over 20 to 30 minutes followed by 0.5 to 1 g per hour. This is not a universal instruction. Evidence is contradictory: a Maharashtra open trial of a higher infusion reported better clinical outcomes, whereas a later double-blind placebo-controlled trial using 2 g then 0.5 g/hour found no survival or ventilation benefit. Compound identity, ageing, salt formulation, delay and regimen affect interpretation. Follow a current toxicologist or poison-centre protocol, check whether the stocked product is chloride or another salt, use weight-based paediatric guidance, monitor blood pressure and avoid a rapid bolus.
Use benzodiazepines for seizures and severe agitation after correcting hypoxia and atropine excess. Antibiotics are not antidotes and are reserved for documented aspiration pneumonia or another infection. Prophylactic furosemide, corticosteroids, magnesium, sodium bicarbonate, haemoperfusion or fresh frozen plasma lack a routine role. Pregnancy does not justify withholding maternal resuscitation or atropine. Dose and route decisions must incorporate ventilation, renal function, co-ingestion and actual formulation, with contemporaneous poison-centre advice.
When to Refer
Call an Indian poison information centre immediately for an unknown formulation, symptomatic exposure, deliberate ingestion, a child, pregnancy, mixed poisoning, unusual clinical course or uncertainty about atropine, oxime or decontamination. AIIMS National Poisons Information Centre advertises round-the-clock advice at toll-free 1800 116 117, but facilities should verify and display current local and regional contacts rather than rely on a guide copied into a poster. Consultation does not replace emergency transfer when respiratory support is unavailable.
Transfer any patient with bronchorrhoea, bronchospasm, hypoxaemia, weakness, fasciculation, altered consciousness, seizures, haemodynamic instability, significant atropine requirement or suspected concentrated ingestion to a monitored hospital. Arrange critical-care or anaesthetic review early when intubation may be needed. During transport use trained staff, oxygen, suction, bag-mask capability, monitoring and sufficient atropine; decontaminate before entering a confined ambulance when feasible. Provide the receiving team with product details, route, time, observations, atropine boluses and infusion, oxime formulation and dose, decontamination, ventilation and co-ingestant findings.
After acute recovery, refer persistent proximal weakness to critical care and neurology or rehabilitation as indicated. New distal weakness, foot drop, paraesthesia or gait change in following weeks needs neurological evaluation for delayed neuropathy. Intentional exposure requires mental-health assessment and a rapid follow-up plan, not simply a signature against medical advice. Occupational cases may need workplace health review, safe spraying education and appropriate statutory or public-health reporting.
Red Flags
A silent or quieter chest is not automatically improvement: it may reflect exhausted ventilation, mucus plugging or minimal air entry. Cyanosis, falling saturation, hypercapnia, a weak cough, inability to lift the head, paradoxical breathing, apnoeic spells or declining consciousness require immediate airway action. Copious secretions and wheeze that recur during an atropine infusion mean inadequate muscarinic control until another cause is shown. Aspiration can produce focal crepitations that do not clear with atropine.
Seizures, severe agitation, coma, profound bradycardia, QT abnormality, ventricular dysrhythmia, shock, rising lactate or recurrent vomiting identify high-risk poisoning or co-ingestion. Do not dismiss tachycardia as proof of adequate treatment if lungs remain wet or pressure is poor. Conversely, a hot, dry, confused patient with urinary retention and ileus may have atropine toxicity. Hyperthermia is particularly dangerous when sweating is blocked.
After apparent cholinergic recovery, new neck-flexor, bulbar, proximal limb or respiratory weakness over roughly one to four days suggests intermediate syndrome and can progress without renewed secretions or miosis. Recurrent wet signs may occur for days with lipophilic compounds and require renewed titration. Weeks later, distal pain, paraesthesia, weakness, foot drop or spasticity can indicate delayed neuropathy. Any renewed suicidal intent, inability to ensure pesticide separation, domestic violence or unsafe discharge environment is also a red flag. A patient should not leave solely because the cholinergic signs have abated.
Indian Clinical Context
Indian care spans subcentres, primary facilities, district hospitals, private emergency departments and tertiary toxicology units with uneven access to ventilators, arterial gases, cholinesterase assays and pralidoxime. The safest protocol therefore centres on actions possible everywhere: PPE, removal from exposure, soap-and-water decontamination, airway positioning and suction, oxygen, bag-mask ventilation, early atropine, glucose, monitoring and organised transfer. A facility that stocks pesticide antidotes must standardise ampoule concentration, keep calculation aids beside the drug and rehearse infusion preparation to prevent tenfold errors.
The DGHS Point of Entry Field Manual instructs staff to use PPE, remove and discard contaminated clothing, wash skin immediately with soap and water and transfer the exposed person to a healthcare facility. These principles apply beyond ports. NCDC maintains a list of poison information centres, and AIIMS NPIC offers 24-hour advice. Clinicians should use the service while the formulation and patient are in front of them; a generic internet table cannot account for a proprietary mixture or local antidote salt.
Prevention needs agriculture, regulation, health and community partners. Locked storage away from homes, original containers, smaller pack sizes, safer substitutes, enforced labelling, PPE suited to heat, equipment maintenance and disposal all matter. After self-poisoning, returning the same container to the bedside household without a safety plan recreates immediate risk. Mental-health care should be confidential and culturally responsive, addressing financial and interpersonal drivers without blaming the patient or farming family.
Evidence limits must be explicit. Much dosing literature is older, comes from Sri Lanka or selected Indian centres, and combines chemically different pesticides. Hospital case fatality cannot be generalised to community incidence. Oxime benefit remains disputed and an enzyme value is not a substitute for physiology. Local audit should capture named agents, time to atropine, intubation delay, medication error and follow-up, then use those findings to improve procurement and transfer pathways.
NMC Competency Mapping
The 2024 Competency Based Medical Education curriculum expects graduates to recognise common poisonings, begin emergency care, understand antidote principles and communicate safely within professional limits. Organophosphorus poisoning integrates pharmacology of cholinergic transmission and atropine, forensic and community aspects of pesticide exposure, medicine and anaesthesia resuscitation, psychiatry after self-harm, and occupational or environmental prevention. Exact competency codes and wording should be checked against the official curriculum before they are placed in a logbook or assessment blueprint.
A graduating learner should obtain a product, route, timing and intent history without delaying ABC care; identify muscarinic, nicotinic and central features; distinguish bronchorrhoea from aspiration; and interpret cholinesterase results as supportive rather than definitive. They should demonstrate safe PPE and clothing removal, call for suction and ventilation, describe atropine endpoints, calculate a doubling bolus sequence and infusion from a documented loading dose, and explain why pupil size is not the endpoint. They should recognise intermediate syndrome, delayed neuropathy and atropine toxicity.
Competence has boundaries. An undergraduate should not independently prescribe prolonged oxime treatment, perform gastric lavage, choose an unmonitored sedative regimen or declare a patient psychiatrically safe. Simulation should include contaminated arrival, a wet hypoxic chest, a calculation check, a later weak-neck examination and a compassionate self-harm conversation. Assessment should reward early airway and atropine decisions, clear documentation, escalation and honest uncertainty more than recital of the SLUDGE mnemonic. Interprofessional learning should include nursing infusion checks, pharmacist confirmation of pralidoxime salt, ambulance transfer planning and poison-centre communication.
Key Exam Pearls for NEET PG
Organophosphorus compounds inhibit acetylcholinesterase, increasing acetylcholine at muscarinic, nicotinic and central synapses. Muscarinic excess produces bronchorrhoea, bronchospasm, salivation, sweating, vomiting, diarrhoea, urination, miosis and often bradycardia. Nicotinic effects include fasciculation followed by weakness and may also cause tachycardia or hypertension. Central toxicity causes agitation, seizures, coma and respiratory depression. Respiratory death is multifactorial: secretions, bronchospasm, aspiration, central depression and neuromuscular failure.
Diagnosis is clinical. Plasma pseudocholinesterase is sensitive to exposure but has biological variation and imperfect severity correlation; red-cell acetylcholinesterase more closely reflects neuronal enzyme. Atropine reverses muscarinic effects but not neuromuscular weakness. Give repeated intravenous atropine with rapid reassessment and dose doubling until the chest clears and perfusion improves, then use a response-titrated infusion. Mydriasis is neither required nor a safe target. Pralidoxime reactivates inhibited enzyme before ageing, but effectiveness varies by compound and timing and trial evidence is inconsistent.
Intermediate syndrome usually appears after the acute cholinergic phase with neck, proximal, bulbar and respiratory weakness; it may require ventilation despite dry lungs. Organophosphate-induced delayed neuropathy appears later with distal sensory-motor dysfunction. Succinylcholine paralysis may be prolonged because cholinesterase activity is depressed. Gastric decontamination never precedes resuscitation and is not routine. Dermal exposure demands PPE, clothing removal and soap-and-water washing.
Carbamate poisoning can closely mimic the syndrome and also responds to atropine, although inhibition is usually reversible. A wet chest with hypoxia is the dominant treatment cue. In an exam vignette, the best first antidotal step in clinically significant cholinergic toxicity is correctly titrated atropine alongside ABC support, not waiting for a cholinesterase report, forcing emesis or giving pralidoxime before airway care.
Frequently Asked Questions
What clinical finding should guide atropine treatment in organophosphorus poisoning?
The most important endpoint is improved respiratory and circulatory physiology: bronchial secretions and bronchospasm resolve, air entry and oxygenation improve, and heart rate and blood pressure support perfusion. Pupil dilation or a dry mouth alone should not drive dosing, and focal crackles from aspiration may persist despite adequate atropine.
Does a normal cholinesterase result exclude organophosphorus poisoning?
No. Assay type, timing, laboratory range, baseline variation and the particular compound all affect interpretation. Plasma butyrylcholinesterase and red-cell acetylcholinesterase can support the diagnosis, but neither should postpone atropine or airway management when the bedside toxidrome is convincing. Repeating a clinically useful assay may help follow exposure, but treatment remains physiology-led.
Should pralidoxime be given to every patient with a suspected pesticide exposure?
Not automatically. It is generally considered early for moderate or severe organophosphorus poisoning, but trials and compounds differ and benefit remains uncertain. The product identity, time, clinical severity, stocked oxime salt and local protocol should be reviewed with a poison centre or toxicologist; atropine and ventilation must not be delayed.
When is an apparently recovered patient still at respiratory risk?
Risk persists after secretions improve because intermediate syndrome can produce neck, bulbar, proximal and respiratory weakness over the next several days, while lipophilic compounds can cause recurrent cholinergic features. Serial respiratory and strength assessment, monitored observation and clear transfer thresholds are necessary rather than discharge based only on dry lungs.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic